$GILD Recent Headlines
Visa shares rise after hours on earnings beat 6:50 p.m. Oct. 29, 2014 - Sue Chang
Warren Buffett best wear his trunks as Fed preps to end (pause) the printing 8:34 a.m. Oct. 29, 2014 - Shawn Langlois
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Updates, advisories and surprises 5:01 p.m. Oct. 28, 2014 - MarketWatch
Sales of Gilead's pricey hepatitis C drug slow 4:26 p.m. Oct. 28, 2014 - MarketWatch.com
Gilead Sciences' stock pulls back from record high close after earnings miss 4:14 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead's stock drops 3.6% in after-hours trade after Q3 results 4:09 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead revises 2014 product sales outlook to $22 bln-$23 bln from $21 bln-$23 bln 4:08 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead Q3 Sovaldi sales $2.8 bln vs. $3.48 bln in Q2 4:07 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead Q3 sales top FactSet consensus estimate of $5.99 bln 4:07 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead Q3 sales $6.04 bln vs. $2.78 bln a year ago 4:07 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead Q3 net EPS $1.67 vs. 47 cents a year ago 4:06 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead Sciences Q3 adj. EPS $1.84 vs. FactSet consensus $1.92 4:06 p.m. Oct. 28, 2014 - Tomi Kilgore
Two biotech leaders to watch 2:12 p.m. Oct. 28, 2014 - The Trading Deck
Charting a bullish year-end backdrop 12:13 p.m. Oct. 28, 2014 - Michael Ashbaugh
Charting a bullish year-end backdrop 11:53 a.m. Oct. 28, 2014 - Michael Ashbaugh
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks 8:35 a.m. Oct. 28, 2014 - Shawn Langlois
Energy, health care earnings to dominate week 5:02 a.m. Oct. 26, 2014 - Wallace Witkowski
Caution is still the word for speculators 3:12 p.m. Oct. 23, 2014 - The Trading Deck
10 stocks loved by advisers who beat bear markets 7:35 p.m. Oct. 15, 2014 - Mark Hulbert
Is AbbVie's Bullishness On Its Hepatitis C Drugs Valid? 8:38 a.m. Today - Seeking Alpha
'Fast Money' Recap: Lower Oil Prices a Warning Sign for Stocks 5:00 a.m. Today - TheStreet.com
CNBC's Stock Pops & Drops From November 3: GoPro, Gilead Sciences And More 7:17 p.m. Nov. 3, 2014 - benzinga.com
Earnings Growth Strong As U.S. Trumps World 4:31 p.m. Nov. 3, 2014 - Investors Business Daily
Consider The 2-3x Upside In This Most Overlooked Hepatitis B Stock 3:53 p.m. Nov. 3, 2014 - Seeking Alpha
Bristol-Myers preparing to follow Gilead's lead on HCV drug pricing 3:23 p.m. Nov. 3, 2014 - Seeking Alpha
Seattle Genetics Gains on Narrower-than-Expected Q3 Loss - Analyst Blog 12:50 p.m. Nov. 3, 2014 - Zacks.com
Gilead: Slaying The Last Dragons Of Doubt? 12:18 p.m. Nov. 3, 2014 - Seeking Alpha
3 Stocks Dragging In The Drugs Industry 12:08 p.m. Nov. 3, 2014 - TheStreet.com
Cramer Sees HP Entering Sector as Trouble for 3-D Printing Stocks 11:57 a.m. Nov. 3, 2014 - TheStreet.com
Novo Nordisk's Earnings Rise in Q3, 2014 Outlook Narrowed - Analyst Blog 11:10 a.m. Nov. 3, 2014 - Zacks.com
Gilead's EPS Miss Is Investors' Gain: Gilead's A Buy On Harvoni Success 8:49 a.m. Nov. 3, 2014 - Seeking Alpha
Why Did Gilead Drop Friday? Is It Justified Or Just An Overreaction? 8:41 a.m. Nov. 3, 2014 - Seeking Alpha
Surging Earnings Estimates Signal Good News for Gilead (GILD) - Tale of the Tape 8:40 a.m. Nov. 3, 2014 - Zacks.com
Super Important Biotech and Drug Stock Events for November 8:24 a.m. Nov. 3, 2014 - TheStreet.com
IBD 50 Caps Impressive 2-Week Rally 5:47 p.m. Oct. 31, 2014 - Investors Business Daily
Gilead Sciences has Multiple Growth Drivers 5:09 p.m. Oct. 31, 2014 - GuruFocus.com
Fundamentals, Technicals Still Intact At Gilead Sciences 4:36 p.m. Oct. 31, 2014 - Investors Business Daily
AbbVie boosts outlook, says strong results reduce need for big deal 2:42 p.m. Oct. 31, 2014 - Seeking Alpha
AbbVie Beats Q3 Earnings Estimates, Raises Guidance 1:25 p.m. Oct. 31, 2014 - Investors Business Daily
Earnings Forecast Buzz for Alibaba, GT Advanced Technologies, GoPro, Plug Power, Gilead Sciences, and American Realty Capital Properties 8:45 a.m. Today - PR Newswire - PRF
Life-Science New Build Report: 200 New North American Sites in Planning Represent Potential $15 Billion Investment, an Industrial Info News Alert 6:16 a.m. Today - Marketwired
Gilead Sciences Once Again Tops the List of California's Most Honored Companies in Institutional Investor's All-America Executive Team Ranking 6:15 a.m. Today - Marketwired
Earnings Forecast Buzz for American Realty Capital Properties, Alibaba, Petroleo Brasileiro Petrobras SA, Gilead Sciences, RF Micro Devices, and GoPro 8:45 a.m. Oct. 30, 2014 - PR Newswire - PRF
Compliance Notice, Dividend Announcements, New Share Repurchase Program, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Edwards and Lilly 8:35 a.m. Oct. 29, 2014 - PR Newswire - PRF
Gilead Sciences Announces Third Quarter 2014 Financial Results 4:09 p.m. Oct. 28, 2014 - BusinessWire - BZX
Earnings Forecast Research for DryShips, GoPro, Gilead Sciences, MannKind, GT Advanced Technologies, and Amazon 8:45 a.m. Oct. 27, 2014 - PR Newswire - PRF
Gilead Sciences to Release Third Quarter 2014 Financial Results on Tuesday, October 28, 2014 5:00 p.m. Oct. 21, 2014 - BusinessWire - BZX
Acquisition Updates, Drug Approval, Drug Development Discontinuation, and Contract Update - Research Reports on AbbVie, Gilead, Pfizer, Lilly and Aetna 8:35 a.m. Oct. 20, 2014 - PR Newswire - PRF
Health Canada Issues Notice of Compliance for Gilead’s Harvoni™ (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C 1:30 p.m. Oct. 16, 2014 - BusinessWire - BZX
Critical Alerts For Tesla Motors, Tekmira Pharmaceuticals, Gilead Sciences, 3D Systems and TASER International Released By InvestorsObserver 9:31 a.m. Oct. 15, 2014 - PR Newswire - PRF
Pre-market Biotech Picks - Gilead Sciences, MannKind, IsoRay, Orexigen Therapeutics, and Sunesis Pharma 9:00 a.m. Oct. 14, 2014 - PR Newswire - PRF
U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C 1:54 p.m. Oct. 10, 2014 - BusinessWire - BZX
Marketing Application Update, Acquisitions, Collaborations, FDA Approvals, and Structural Changes - Research Reports on Gilead, BD, Pfizer, AbbVie and Novartis 8:55 a.m. Oct. 10, 2014 - PR Newswire - PRF
Positive Study Results, Acquisitions, Drug Approval, Regulatory Updates, and Collaborations - Research Reports on Gilead, Pfizer, AbbVie, Pacira and Thermo Fisher 8:50 a.m. Sept. 30, 2014 - PR Newswire - PRF
European CHMP Adopts Positive Opinion for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults 7:18 a.m. Sept. 26, 2014 - BusinessWire - BZX
Critical Alerts For Gilead Sciences, Ambarella, American Capital Agency, NetApp and Ford Released By InvestorsObserver 10:33 a.m. Sept. 24, 2014 - PR Newswire - PRF
Critical Alerts For Gilead Sciences, Ambarella, American Capital Agency, NetApp and Ford Released By InvestorsObserver 9:37 a.m. Sept. 24, 2014 - PR Newswire - PRF
Gilead’s Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies 8:30 a.m. Sept. 24, 2014 - BusinessWire - BZX
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Fixed-Dose Combination of Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 1 Infection 12:00 a.m. Sept. 24, 2014 - BusinessWire - BZX
Visa shares rise after hours on earnings beat 6:50 p.m. Oct. 29, 2014 - Sue Chang
Warren Buffett best wear his trunks as Fed preps to end (pause) the printing 8:34 a.m. Oct. 29, 2014 - Shawn Langlois
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Updates, advisories and surprises 5:01 p.m. Oct. 28, 2014 - MarketWatch
Sales of Gilead's pricey hepatitis C drug slow 4:26 p.m. Oct. 28, 2014 - MarketWatch.com
Gilead Sciences' stock pulls back from record high close after earnings miss 4:14 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead's stock drops 3.6% in after-hours trade after Q3 results 4:09 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead revises 2014 product sales outlook to $22 bln-$23 bln from $21 bln-$23 bln 4:08 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead Q3 Sovaldi sales $2.8 bln vs. $3.48 bln in Q2 4:07 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead Q3 sales top FactSet consensus estimate of $5.99 bln 4:07 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead Q3 sales $6.04 bln vs. $2.78 bln a year ago 4:07 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead Q3 net EPS $1.67 vs. 47 cents a year ago 4:06 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead Sciences Q3 adj. EPS $1.84 vs. FactSet consensus $1.92 4:06 p.m. Oct. 28, 2014 - Tomi Kilgore
Two biotech leaders to watch 2:12 p.m. Oct. 28, 2014 - The Trading Deck
Charting a bullish year-end backdrop 12:13 p.m. Oct. 28, 2014 - Michael Ashbaugh
Charting a bullish year-end backdrop 11:53 a.m. Oct. 28, 2014 - Michael Ashbaugh
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks 8:35 a.m. Oct. 28, 2014 - Shawn Langlois
Energy, health care earnings to dominate week 5:02 a.m. Oct. 26, 2014 - Wallace Witkowski
Caution is still the word for speculators 3:12 p.m. Oct. 23, 2014 - The Trading Deck
10 stocks loved by advisers who beat bear markets 7:35 p.m. Oct. 15, 2014 - Mark Hulbert
Is AbbVie's Bullishness On Its Hepatitis C Drugs Valid? 8:38 a.m. Today - Seeking Alpha
'Fast Money' Recap: Lower Oil Prices a Warning Sign for Stocks 5:00 a.m. Today - TheStreet.com
CNBC's Stock Pops & Drops From November 3: GoPro, Gilead Sciences And More 7:17 p.m. Nov. 3, 2014 - benzinga.com
Earnings Growth Strong As U.S. Trumps World 4:31 p.m. Nov. 3, 2014 - Investors Business Daily
Consider The 2-3x Upside In This Most Overlooked Hepatitis B Stock 3:53 p.m. Nov. 3, 2014 - Seeking Alpha
Bristol-Myers preparing to follow Gilead's lead on HCV drug pricing 3:23 p.m. Nov. 3, 2014 - Seeking Alpha
Seattle Genetics Gains on Narrower-than-Expected Q3 Loss - Analyst Blog 12:50 p.m. Nov. 3, 2014 - Zacks.com
Gilead: Slaying The Last Dragons Of Doubt? 12:18 p.m. Nov. 3, 2014 - Seeking Alpha
3 Stocks Dragging In The Drugs Industry 12:08 p.m. Nov. 3, 2014 - TheStreet.com
Cramer Sees HP Entering Sector as Trouble for 3-D Printing Stocks 11:57 a.m. Nov. 3, 2014 - TheStreet.com
Novo Nordisk's Earnings Rise in Q3, 2014 Outlook Narrowed - Analyst Blog 11:10 a.m. Nov. 3, 2014 - Zacks.com
Gilead's EPS Miss Is Investors' Gain: Gilead's A Buy On Harvoni Success 8:49 a.m. Nov. 3, 2014 - Seeking Alpha
Why Did Gilead Drop Friday? Is It Justified Or Just An Overreaction? 8:41 a.m. Nov. 3, 2014 - Seeking Alpha
Surging Earnings Estimates Signal Good News for Gilead (GILD) - Tale of the Tape 8:40 a.m. Nov. 3, 2014 - Zacks.com
Super Important Biotech and Drug Stock Events for November 8:24 a.m. Nov. 3, 2014 - TheStreet.com
IBD 50 Caps Impressive 2-Week Rally 5:47 p.m. Oct. 31, 2014 - Investors Business Daily
Gilead Sciences has Multiple Growth Drivers 5:09 p.m. Oct. 31, 2014 - GuruFocus.com
Fundamentals, Technicals Still Intact At Gilead Sciences 4:36 p.m. Oct. 31, 2014 - Investors Business Daily
AbbVie boosts outlook, says strong results reduce need for big deal 2:42 p.m. Oct. 31, 2014 - Seeking Alpha
AbbVie Beats Q3 Earnings Estimates, Raises Guidance 1:25 p.m. Oct. 31, 2014 - Investors Business Daily
Earnings Forecast Buzz for Alibaba, GT Advanced Technologies, GoPro, Plug Power, Gilead Sciences, and American Realty Capital Properties 8:45 a.m. Today - PR Newswire - PRF
Life-Science New Build Report: 200 New North American Sites in Planning Represent Potential $15 Billion Investment, an Industrial Info News Alert 6:16 a.m. Today - Marketwired
Gilead Sciences Once Again Tops the List of California's Most Honored Companies in Institutional Investor's All-America Executive Team Ranking 6:15 a.m. Today - Marketwired
Earnings Forecast Buzz for American Realty Capital Properties, Alibaba, Petroleo Brasileiro Petrobras SA, Gilead Sciences, RF Micro Devices, and GoPro 8:45 a.m. Oct. 30, 2014 - PR Newswire - PRF
Compliance Notice, Dividend Announcements, New Share Repurchase Program, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Edwards and Lilly 8:35 a.m. Oct. 29, 2014 - PR Newswire - PRF
Gilead Sciences Announces Third Quarter 2014 Financial Results 4:09 p.m. Oct. 28, 2014 - BusinessWire - BZX
Earnings Forecast Research for DryShips, GoPro, Gilead Sciences, MannKind, GT Advanced Technologies, and Amazon 8:45 a.m. Oct. 27, 2014 - PR Newswire - PRF
Gilead Sciences to Release Third Quarter 2014 Financial Results on Tuesday, October 28, 2014 5:00 p.m. Oct. 21, 2014 - BusinessWire - BZX
Acquisition Updates, Drug Approval, Drug Development Discontinuation, and Contract Update - Research Reports on AbbVie, Gilead, Pfizer, Lilly and Aetna 8:35 a.m. Oct. 20, 2014 - PR Newswire - PRF
Health Canada Issues Notice of Compliance for Gilead’s Harvoni™ (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C 1:30 p.m. Oct. 16, 2014 - BusinessWire - BZX
Critical Alerts For Tesla Motors, Tekmira Pharmaceuticals, Gilead Sciences, 3D Systems and TASER International Released By InvestorsObserver 9:31 a.m. Oct. 15, 2014 - PR Newswire - PRF
Pre-market Biotech Picks - Gilead Sciences, MannKind, IsoRay, Orexigen Therapeutics, and Sunesis Pharma 9:00 a.m. Oct. 14, 2014 - PR Newswire - PRF
U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C 1:54 p.m. Oct. 10, 2014 - BusinessWire - BZX
Marketing Application Update, Acquisitions, Collaborations, FDA Approvals, and Structural Changes - Research Reports on Gilead, BD, Pfizer, AbbVie and Novartis 8:55 a.m. Oct. 10, 2014 - PR Newswire - PRF
Positive Study Results, Acquisitions, Drug Approval, Regulatory Updates, and Collaborations - Research Reports on Gilead, Pfizer, AbbVie, Pacira and Thermo Fisher 8:50 a.m. Sept. 30, 2014 - PR Newswire - PRF
European CHMP Adopts Positive Opinion for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults 7:18 a.m. Sept. 26, 2014 - BusinessWire - BZX
Critical Alerts For Gilead Sciences, Ambarella, American Capital Agency, NetApp and Ford Released By InvestorsObserver 10:33 a.m. Sept. 24, 2014 - PR Newswire - PRF
Critical Alerts For Gilead Sciences, Ambarella, American Capital Agency, NetApp and Ford Released By InvestorsObserver 9:37 a.m. Sept. 24, 2014 - PR Newswire - PRF
Gilead’s Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies 8:30 a.m. Sept. 24, 2014 - BusinessWire - BZX
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Fixed-Dose Combination of Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 1 Infection 12:00 a.m. Sept. 24, 2014 - BusinessWire - BZX
